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ABSTRACT 
A facile and an efficient protocol for the synthesis of pyridazinones via 
molecular-iodine-mediated cleavage of 4-bromomethylcoumarin 
precursors in the presence of I2 in ethanol at 70 °C is reported. The 
present approach replaced the basic condition (K2CO3) with Lewis 
acidic condition.  
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Introduction 
Nitrogen-containing heterocycles are of biological importance, and the design of newer 
strategies for their synthesis is an important area of research in organic chemistry.[1–4] 
Pyridazines and pyridazinones are important structures in the development of new bio-
active compounds and several of them have been used in the treatment of many human 
pathologies.[5,6] Pyridazinones have attracted much attention in synthetic and medicinal 
chemistry because of their useful biological activities and exceptional pharmacological 
properties.[7] A large number of compounds bearing pyridazinone scaffolds have entered 
preclinical and clinical tests over the past few years. Many commercially available drugs 
(Fig. 1), including Zardaverine (phosphodiesterase inhibitor),[8,9] Emorfazone (the efficacy 
of this drug on post-surgical dental pain and inflammation is lacking),[10] and CEP-26401 
(Irdabisant, potent histamine H3 receptor (H3R) antagonist/inverse agonist with drug-like 
properties),[11] are derived from 1,2-pyridazin-3-one core entities. 
Pyridazinone-based compounds have been associated with valuable biological activities 
such as antiviral,[12] anti-inflammatory,[13] antinociceptive,[14] antiplatelet,[15] anticancer,[16] 
antiangiogenic agents,[17] and acetylcholinesterase inhibitors.[18] Hence, the synthesis of 
pyridazinones has evoked much attention, as a result of which a variety of synthetic 
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methodologies have been reported. The most important approaches are (i) from chiral 
β-methy-√-ketocarboxylic acid,[19] (ii) retro-ene-assisted palladium-catalyzed synthesis of 
4,5-disubstituted-3(2H)-pyridazinones,[20] (iii) concise synthesis of ω-fluoroalkylated 
ketoesters, a building block for the synthesis of six-, seven-, and eight-membered fluoroalkyl 
substituted 1,2-diaza-3-one heterocycles,[21] (iv) cyclocondensation of arylhydrazine with 1,4- 
difunctionalized compound,[22] and (v) from coumarins and hydrazine. Other methods have 
also been developed within the past three decades.[23] The recent method developed by 
Kulkarni et al. is based on a base catalyst such as K2CO3, and has its own limitations such 
as use of excess amount of toxic, metal carbonate base and moderate yields. Thus, develop-
ment of a convenient and efficient strategy to establish pyridazinone entities is still interesting 
in the realm of synthetic and medicinal organic chemistry. To the best of our knowledge, this 
is the first report on the use of Lewis acid condition to synthesize the pyridazinones. 
In recent years, molecular iodine, a mild Lewis acid, has been used in plethora of func-
tional group transformations in organic synthesis. The mild Lewis acidity associated with 
iodine has enhanced its usage in organic synthesis to realize several organic transforma-
tions using catalytic amounts to stoichiometric levels. Owing to numerous advantages 
associated with iodine, it has been explored as a powerful catalyst for various organic 
transformations. Molecular iodine has emerged as an inexpensive, nontoxic, nonmetallic, 
readily available, and environmentally benign catalyst for various organic transformations, 
which have been reviewed recently.[24–27] 
Results and discussion 
4-Bromomethylcoumarins are prepared as per literature reports.[28–34] During the course of 
our initial investigations, the reaction of 4-bromomethyl-6-ethylcoumarin (1d) and 
benzohydrazide (2) was used as a model reaction for the optimization of the reaction 
conditions (Scheme 1). The control experiment in the absence of catalyst was first carried 
out for 48 h and the target compound (3d) was not obtained because of poor reactivity of ben-
zohydrazide. We hypothesized that iodine catalyzes the reaction. A preliminary examination 
showed that I2 in ethanol among several solvents effectively catalyzed the model reaction. Next, 
the catalyst loading was investigated and it was found that 10 mol% of iodine was enough for 
the model reaction to obtain the target compound (3d) in an excellent yield of 96%. Thus, 
10 mol% of iodine was selected as an optimal catalyst loading for further investigations. 
To determine the optimum reaction conditions, the effect of other reaction param-
eters such as the solvent, temperature, and reaction time were investigated. Several 
other solvents including acetonitrile, dichloromethane (DCM), tetrahydrofuran (THF), 
Figure 1. Commercial drugs containing pyridazinone moieties.  
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dimethylformamide (DMF), toluene, chloroform, dimethylsulfoxide (DMSO), and 
1,4-dioxane were screened but lower yields were obtained (Table 1, entries 5–12). So in this 
reaction, ethanol was used as a solvent. In addition, the effect of temperature and reaction 
time were also studied (Table 1, entries 1–4 and 13–15). It was found that neither increas-
ing nor decreasing the reaction time and temperature could enhance the yield. Therefore, 
this reaction could be best carried out with 10 mol% of iodine as catalyst in ethanol at 70 °C 
for 12 h. This remarkable activation in reaction rate prompted us to explore the potential of 
this protocol for the synthesis of series of 2-benzoyl-5-(2-hydroxyphenyl)-pyridazin-3(2H)- 
ones. All the aforementioned reactions proceeded expeditiously and delivered good to 
excellent yields. The overall yield ranged from 96% of 2- benzoyl-5-(5-ethyl-2-hydroxy-
phenyl)-pyridazin-3(2H)-one (3d) to 83% of 2-benzoyl-5-(5-fluoro-2-hydroxyphenyl)- 
pyridazin-3(2H)-one (3l). 
Mechanism 
A reasonable mechanism for the formation of 2-benzoyl-5-(2-hydroxyphenyl)-pyridazin-3 
(2H)-one is illustrated (Scheme 2), which is similar to the established mechanism.[35] 
Nucleophilic attack of benzohydrazide on the methylene group followed by an intramol-
ecular nucleophilic attack of the nitrogen lone pairs on the lactone carbonyl results in 
the intermediate, which undergo in situ dehydrogenation to give 2-benzoyl-5-(2-hydroxy-
phenyl)-pyridazin-3(2H)-one. 
Scheme 1. Iodine-catalyzed synthesis of pyridazinone derivatives.  
Table 1. Optimization of the model reaction (3d). 
Entry Temp. (°C) Solvent Time (h) Yield (%)  
1 rt Ethanol  48 15 
2 40 Ethanol  24 52 
3 60 Ethanol  18 68 
4 70 Ethanol  12 96 
5 70 Acetonitrile  12 72 
6 70 DCM  12 67 
7 70 THF  12 74 
8 70 DMF  12 51 
9 70 Toluene  12 58 
10 70 Chloroform  12 77 
11 70 DMSO  12 75 
12 70 1,4-Dioxane  12 70 
13 70 Ethanol  5 40 
14 70 Ethanol  8 66 
15 70 Ethanol  24 90  
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Conclusion 
In conclusion, we have developed a facile and an efficient procedure for the synthesis of novel 
2-benzoyl-5-(2-hydroxyphenyl)-pyridazin-3(2H)-ones from 4-bromomethylcoumarins and 
benzohydrazide in the presence of iodine as a catalyst. This method provides biologically 
interesting pyridazinone derivatives in good to excellent yields. 
Exprimental 
Commercially available reagents were used without further purification. The melting 
points were measured with an electric melting point apparatus and were not corrected. 
The infrared (IR) spectra were recorded on a Shimadzu-8400S FT-IR spectrophotometer 
(KBr disks). 1H NMR (400 MHz) and13C NMR (100 MHz) spectra were recorded in 
CDCl3/DMSO-d6 as solvent with a Bruker spectrometer using tetramethylsilane (TMS) 
as an internal standard. Chemical shifts were expressed in parts per million (ppm). The 
high-resolution mass spectrum (HRMS) was recorded at IISC, Bangalore. Elemental analy-
sis for C, H, and N were performed with an Elemental Vario Micro Cube CHN Rapid 
Analyzer. All the compounds gave satisfactory elemental analysis. 
General procedure for the synthesis of 2-benzoyl-5-(5-ethyl-2-hydroxyphenyl)- 
pyridazin-3(2H)-one (3d) 
Iodine (10 mol%) was added to a stirring solution of benzohydrazide (0.5 g, 3.6 mmol) in 
ethanol (10 ml), which was heated to 70 °C in an oil bath. Later 6-ethyl-4-bromomethyl-
coumarin (0.98 g, 3.6 mmol) was added and refluxing was continued for 12 h. After 
Scheme 2. Reasonable mechanism for the synthesis of novel pyridazinone derivatives.  
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completion of the reaction, ethanol was removed under reduced pressure. The residue left 
out was dissolved with ethyl acetate and added aqueous Na2S2O3 solution. The organic 
layer was separated and the aqueous layer was extracted with ethyl acetate. The combined 
organic phase was washed with water, dried over anhydrous sodium sulfate, and concen-
trated in vacuo. The crude product was purified by column chromatography on silica gel 
[eluent: hexane and ethyl acetate (7:3)] to afford the product as a colorless solid. 
2-Benzoyl-5-(5-ethyl-2-hydroxyphenyl)-pyridazin-3(2H)-one (3d) 
Yield 96%; colorless solid; mp 225 °C; IR (KBr, cm  1): 1679, 1726 (C=O), 3402 (OH); 1H 
NMR (400 MHz, CDCl3): δ 1.25 (t, 3H, CH3 of ethyl group, J1,2 ¼ 7.6 Hz), 2.61 (q, 2H, CH2 
of ethyl group, J1,2 ¼ 7.6 Hz), 6.78 (s, 1H, Ar-H), 6.89 (s, 1H, Ar-H), 7.36–7.90 (m, 8H, 
Ar-H), 9.17 (s, 1H, OH) ppm; 13C NMR (100 MHz, DMSO-d6): δ 13.7, 33.0, 113.3, 
116.6, 116.7, 122.0, 123.8, 127.1, 127.2, 130.8, 132.7, 132.8, 144.7, 148.6, 150.5, 151.3, 
159.5, 161.9, 163.5 ppm; HR-MS: [MþNa] 343.0000. Anal. calcd. for C19H16N2O3: 
C, 71.24; H, 5.03; N, 8.74. Found: C, 71.19; H, 4.98; N, 8.68. 
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